Janney Montgomery Scott cut shares of Illumina Inc. (NASDAQ:ILMN) from a neutral rating to a sell rating in a research report released on Tuesday. Janney Montgomery Scott currently has $125.00 price objective on the life sciences company’s stock, down from their previous price objective of $155.00.

ILMN has been the topic of a number of other reports. Zacks Investment Research raised shares of Illumina from a sell rating to a hold rating in a research report on Monday, July 4th. CL King downgraded shares of Illumina from a buy rating to a neutral rating in a research report on Monday, August 22nd. Piper Jaffray Cos. reissued an overweight rating and set a $161.00 price objective on shares of Illumina in a research report on Friday, July 15th. Vetr upgraded shares of Illumina from a sell rating to a buy rating and set a $198.61 target price on the stock in a report on Monday, October 3rd. Finally, Cantor Fitzgerald restated a hold rating and set a $165.00 target price on shares of Illumina in a report on Wednesday, July 27th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Hold and an average target price of $159.24.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) traded down 1.60% during mid-day trading on Tuesday, reaching $136.76. 1,225,690 shares of the company were exchanged. The stock has a 50-day moving average price of $174.01 and a 200 day moving average price of $156.43. The company has a market capitalization of $20.05 billion, a PE ratio of 46.84 and a beta of 0.47. Illumina has a one year low of $127.10 and a one year high of $196.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.80 EPS. Analysts predict that Illumina will post $3.53 EPS for the current year.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the stock in a transaction that occurred on Friday, October 7th. The shares were sold at an average price of $184.36, for a total transaction of $110,616.00. Following the completion of the sale, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $3,146,103.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert S. Epstein sold 300 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $170.27, for a total transaction of $51,081.00. Following the sale, the director now directly owns 7,224 shares of the company’s stock, valued at $1,230,030.48. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Physicians Financial Services Inc. increased its position in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new position in Illumina during the second quarter worth approximately $112,000. Ropes Wealth Advisors LLC increased its position in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its position in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. 95.22% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.